Monensin (Synonyms: Monensin A)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Monensin  (Synonyms: Monensin A)

Monensin (Monensin A) 是一种具有口服活性的抗生素 (antibiotic)，是一种介导 Na+/H+ 交换的离子载体。Monensin 是一种有效的 Wnt 信号传导抑制剂。Monensin 导致多泡体（MVB）显着增大并调节外泌体分泌。Monensin 可用于细菌、真菌和寄生虫感染研究，并显示出抗癌作用。

Monensin (Synonyms: Monensin A)

Monensin Chemical Structure

CAS No. : 17090-79-8

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Monensin 的其他形式现货产品:

Monensin sodium

Monensin 相关产品

•同靶点产品:

•同靶点蛋白产品:

生物活性

Monensin (Monensin A), an orally active antibiotic, is an ionophore that mediates Na+/H+ exchange. Monensin is a potent Wnt signaling inhibitor. Monensin causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion. Monensin can be used for bacterial, fungal, and parasitic infections research, and shows anticancer effects[1][2][3][4].

体外研究
(In Vitro)

Monensin（1-5 μM；48 小时）会导致活力显着下降，且呈剂量依赖性[1]。
Monensin（1-5 μM；24 小时）显示出统计显着的细胞凋亡诱导作用[1]。
Monensin（0.1-1 μM；24 小时）抑制 pEGFR 及其下游靶点 pAKT 和 pERK[1]。
SCC25 cells[1] 1 μM, or 5 μM 24 hours Induced a potent apoptotic response. SCC9 and SCC25 cells[1] 0.1 μM, or 1 μM 24 hours Induced approximately a 50% inhibition of EGF-treated SCC9 cells with respect to pEGFR and its downstream targets pAKT and pERK.

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Monensin 相关抗体:

Cell Viability Assay[1]

Cell Line: SCC9, SCC25, and GM-38 cell lines
Concentration: 1-5 μM
Incubation Time: 48 h
Result: Resulted in a marked decrease in viability in a dose-dependent manner.

Apoptosis Analysis[1]

Cell Line: SCC25 cells
Concentration: 1 μM, or 5 μM
Incubation Time: 24 hours
Result: Induced a potent apoptotic response.

Western Blot Analysis[1]

Cell Line: SCC9 and SCC25 cells
Concentration: 0.1 μM, or 1 μM
Incubation Time: 24 hours
Result: Induced approximately a 50% inhibition of EGF-treated SCC9 cells with respect to pEGFR and its downstream targets pAKT and pERK.

体内研究
(In Vivo)

Monensin（10 mg/kg；口服；每日；持续 6 周）可抑制多发性肠道肿瘤 (Min) 小鼠肠道肿瘤的进展，且对正常粘膜没有任何毒性迹象[2]。

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Multiple intestinal neoplasia (Min) mice (four-week-old) [2]
Dosage: 10 mg/kg
Administration: Orally application; daily; for 6 weeks
Result: Suppressed progression of the intestinal tumors without any sign of toxicity on normal mucosa.

分子量

670.87

Formula

C36H62O11
CAS 号

17090-79-8
中文名称

莫能菌素
结构分类
  • Others
初始来源
  • 微生物

Streptomyces spp.
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (549 KB) 产品使用指南 (1538 KB)

参考文献

  • [1]. Dayekh K, et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther. 2014 Nov;13(11):2559-71.  [Content Brief]

    [2]. Tumova L, et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol Cancer Ther. 2014 Apr;13(4):812-22.  [Content Brief]

    [3]. Youhua Huang, et al. Autophagy Participates in Lysosomal Vacuolation-Mediated Cell Death in RGNNV-Infected Cells. Front Microbiol. 2020 Apr 30:11:790.  [Content Brief]

    [4]. Ariel Savina, et al. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic. 2005 Feb;6(2):131-43.  [Content Brief]

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务